A Phase III Trial of Continuous Low-Dose Infusion versus Intermittent High-Dose Infusion of 5-Fluorouracil in Patients with Disseminated Colorectal Cancer
Publication Information Expand/Collapse
PMid: PMID29370458 | PMC number: PMC5963502
The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials
PMid: PMID27986655 | PMC number: PMC5370550
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
Assessment of infusional 5-fluorouracil schedule and dose intensity. a Southwest Oncology Group and Eastern Cooperative Oncology Group study
Phase III trial of protracted infusion (PI) vs intermittent high-dose infusion (HDI) 5-fluorouracil (5-FU) in patients (PTS) with disseminated colorectal cancer (DCRC): a Southwest Oncology Group (SWOG) and Eastern Cooperative Oncology Group (ECOG) study.